Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Imugene Limited ( (AU:IMU) ).
Imugene Limited announced that all resolutions were passed at their Extraordinary General Meeting, as decided by a poll. This outcome supports the company’s strategic direction and reinforces its commitment to advancing its pipeline of immuno-oncology therapies, potentially strengthening its position in the global cancer treatment market.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
More about Imugene Limited
Imugene Limited is a clinical stage immuno-oncology company focused on developing innovative immunotherapies to activate the immune system of cancer patients. Their platform technologies aim to harness the body’s immune system against tumors, with a pipeline that includes an allogeneic cell therapy CAR T drug targeting blood cancers, multiple B-cell vaccine candidates, and an oncolytic virotherapy for various cancers. Imugene is supported by a team of international cancer experts and is committed to transforming cancer treatment.
Average Trading Volume: 18,435,306
Technical Sentiment Signal: Sell
Current Market Cap: A$97.07M
Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.